Stage IIIC ovarian/peritoneal serous carcinoma: A heterogeneous group of patients with different prognoses

International Journal of Gynecological Pathology

Volumn 33, Issue 3, 2014, Pages 302-308

  Bakkar, Rania ^a   Gershenson, David ^b   Fox, Patricia ^b   Vu, Kim ^b   Zenali, Maryam ^c   Silva, Elvio ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF VERMONT   (United States)

Author keywords

FIGO; Ovarian; Peritoneal; Serous

Indexed keywords

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEAL SEROUS CARCINOMA; PERITONEUM CANCER; PERITONEUM METASTASIS; PRIMARY OVARIAN SEROUS CARCINOMA; PRIORITY JOURNAL; CYSTADENOCARCINOMA; FOLLOW UP; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS;

CYSTADENOCARCINOMA, SEROUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS;

EID: 84898600275     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e3182988dfd     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012;62:10-29.
2. Benedet JL, Bender H, Jones H III, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynecol Obstet 2000;70: 209-62.
3. Bloss JD, Liao SY, Buller RE, et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993;50:347-51.
4. Johns Hopkins Pathology. Ovarian cancer. 2001. Available at: http://ovariancancer.jhmi.edu/treatment.cfm. Accessed May 9, 2013.
5. FIGO Cancer Committee. Staging announcement. Gynecol Oncol 1986;25:383-5.
6. The Oncology Committee of the International Federation of Gynecology and Obstetrics. FIGO news: changes to the 1985 FIGO report on the result of treatment in gynaecological cancer. Int J Gynecol Obstet 1987;25:87-8.
7. Meier WJ. Lymphadenectomy in stage I ovarian cancer. Proc Am Soc Clin Oncol 2000;19:1541.
8. Benedetti-Panici P, Greggi S, Maneschi F, et al. Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer. Gynecol Oncol 1993;51:150-54.
9. Petru E, Lahousen M, Tamussino K, et al. Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol 1994;170: 656-62.
10. Baiocchi G, Raspagliesi F, Grosso G, et al. Early ovarian cancer: is there a role for systematic pelvis and para-aortic lymphadenectomy? Int J Gynecol Cancer 1998;8:103-8.
11. Spirtos NM, Gross GM, Freddo JL, et al. Cytoreductive surgery in advanced epithelial cancer of the ovary: the impact of aortic and pelvic lymphadenectomy. Gynecol Oncol 1995; 56:345-52.
12. Sidney S, Chen MD. Survival of ovarian carcinoma with or without lymph node metastasis. Gynecol Oncol 1987;27: 368-72.
13. Lanza A, D'addato F, Valli M, et al. Pelvic and para-aortic lymph nodal positivity in the ovarian carcinoma: its prognostic significance. Eur J Gynaecol Oncol 1988;9:36-9.
14. Altman AD, Nelson G, Chu P, et al. Optimal debulking targets in women with advanced stage ovarian cancer: a retrospective study of immediate versus interval debulking surgery. J Obstet Gynaecol Can 2012;34:558-66.
15. Elattar A, Bryant A, Winter-Roach BA, et al. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2011;10:CD007565.
16. Hacker NF, Berek JS, Lagasse LD, et al. Primary cytoreduc-tive surgery for epithelial ovarian cancer. Obstet Gynecol 1983; 61:413-20.
17. Einhorn N, Nilsson B, Sjovall K. Factors influencing survival in carcinoma of the ovary. Study from a well-defined Swedish population. Cancer 1985;55:2019-25.
18. Hoskins WJ, Bundy BN, Thigpen JT, et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47: 159-66.
19. Farias-Eisner R, Teng F, Oliveira M, et al. The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol 1995;55: 108-10.
20. Killackey MA, Davis AR. Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma. Gynecol Oncol 1993;51:171-4.
21. Strand CM, Grosh WW, Baxter J, et al. Peritoneal carcino-matosis of unknown primary site in women: a distinctive subset of adenocarcinoma. Ann Intern Med 1989;111:213-7.
22. Lele SB, Piver MS, Matharu J, et al. Peritoneal papillary carcinoma. Gynecol Oncol 1988;31:315-20.
23. Ransom DT, Patel SR, Keeney GL, et al. Papillary serous carcinoma of the peritoneum: a review of 33 cases treated with platin-based chemotherapy. Cancer 1990;66:1091-4.
24. Carnino F, Fuda G, Ciccone G, et al. Significance of lymph node sampling in epithelial carcinoma of the ovary. Gynecol Oncol 1997;65:467-72.
25. Chen SS, Lee L. Incidence of para-aortic and pelvic lymph node metastases in epithelial carcinoma of the ovary. Gynecol Oncol 1983;16:95-100.